Type 4 phosphodiesterase inhibitors and their potential in the treatment of inflammatory disease

Bibliography

• WARD JM, MCKENN1FF M, EVANS JM, PAGE CP, COSTELLO J: Theophylline - an immuno-modulatory role in asthma Am. Rev. Resp. Dis. (1993) 147:518–523.
   PubMed Web of Science ®Google Scholar
• SULLIVAN P, BEKIR S,JAFFAR Z, et al.: Anti-inflammatory effects of low-dose oral theophylline in atopic asthma. Lancet (1994) 343:1006–1008.
   PubMed Web of Science ®Google Scholar
• SEARS MR, TAYLOR DR, PRINT CG, et al.: Regular inhaled beta-agonist treatment in bronchial asthma. Lancet (1990) 336:1391–1396.
   PubMed Web of Science ®Google Scholar
• SPITZER WO, SUISSA S, ERNST P, et al.: The use of beta-agonists and the risk of death and near death from asthma. New Engl. I Med. (1992) 326:501–506.
   PubMed Web of Science ®Google Scholar
• ELLIOTT MJ, MAINI RN, FELDMANN M, et al.: Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor a (cA2) versus placebo in rheumatoid arthritis. Lancet (1994) 344:1105–1110.
   PubMed Web of Science ®Google Scholar
• SCHAFER-KORTING M, SCHMID MH, KORTTING HC: Topical glucocorticoids with improved risk benefit ratio. Rationale of a new concept. Drug Safety (1996) 14:375–385.
   PubMed Web of Science ®Google Scholar
• GLOOR M: Therapeutical procedures in atopic dermatitis. TW DermatoL (1995) 25(Suppl.):5–11.
   Google Scholar
• BOWDEN PE: Molecular biology of psoriasis and its future management. J. DermatoL Treat. (1996) 7\(Suppl. 1):S1–S6.
   Google Scholar
• HSIEH KH: Atopic dermatitis: immune indicators and immunomodulatory treatment. Clin. Immunother. (1995) 3:88–93.
   Google Scholar
• LAUERMA AI, MAIBACH HI: Topical FK-506 - clinical potential or laboratory curiosity. Dermatology (1994) 188:173–176.
   PubMed Web of Science ®Google Scholar
• Pharmaprojects Database. PJB Publications Ltd.
   Google Scholar
• BIRD J, MONTANA J: New therapeutic approaches to atopic dermatitis. Exp. Opin. Invest. Drugs (1996) 5:1173–1180.
   Google Scholar
• PALFREYMAN MN, SOUNESS JE: Phosphodiesterase type IV inhibitors. Frog. Med. Chem. (1996) 33:1–52.
   PubMedGoogle Scholar
• BOLGER G: Molecular biology of the cyclic AMP-specific cyclic nucleotide phosphodiesterases: a diverse family of regulatory enzymes. Cell. Signalling (1994) 6:851–859.
   PubMed Web of Science ®Google Scholar
• BEAVO JA, REIFSNYDER DH: Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends PharmacoL Sci. (1990) 11:150–155.
   PubMed Web of Science ®Google Scholar
• Townley RG, Agarwal DK (Eds.), Marcel Dekker, New York (1996):523–560.
   Google Scholar
• Raeburn D, Giem-bycz MA (Eds.), Birkhauser Verlag, Basel (1994):271–308.
   Google Scholar
• ISRAEL E, MATHUR PN, TACHKIN D, DRAZEN JM: LY 168855 prevents bronchospasm in asthma of moderate severity. Chest (1987) 91:71S.
   PubMed Web of Science ®Google Scholar
• HARBINSON PL, SULLIVAN PJ, WAH1D S, et al.: Effect of CDP 840, a selective inhibitor of phosphodiesterase type IV (PDE IV), on the allergen induced asthmatic response. Am. J. Respir. CriL Care Med. (1996) 153:A347.
   Google Scholar
• HAWKSWORTH R, HEATH P, LEE TH: The effects of CDP 840, a potent and selective phos-phodiesterase type IV (PDE IV) inhibitor, on FEVi in patients with bronchial asthma. Am. J. Respir. CriL Care Med. (1996) 153:A347.
   Google Scholar
• MACLEOD D, O'TOOLE S, HEATH P, HOLGATE S: Evaluation of the safety and protection against histamine of a new selective phosphodiesterase inhibitor, CDP 840, in mild asthma. Am. Respir. CriL Care Med. (1996) 153:A347.
   Google Scholar
• SOUNESS JE, GRIFFIN M, MASLEN C, et al.: Evidence that cyclic AIVIP phosphodiesterase inhibitors suppress TNF-a generation from human monocytes by interacting with a 'low-affinity' phosphodiesterase 4 conformer. Br. J. PharmacoL (1996) 118:649–658.
   PubMed Web of Science ®Google Scholar
• KAMBAYASHI T, JACOB CO, ZHOU D, et al.: Cyclic nucleotide phosphodiesterase type IV participates in the regulation of IL-10 and the subsequent inhibition of TNF-a and IL-6 release by endotoxin-stimulated macrophages. I ImmunoL (1995) 155:4909–4916.
   Web of Science ®Google Scholar
• WILLIAMS RO, FELDMAN M, MAINI RN: Anti-tumour necrosis factor ameliorates joint disease in murine collagen-induced arthritis. Proc. Natl. Acad. Sci. USA (1992) 89:9784–9788.
   PubMed Web of Science ®Google Scholar
• TANAKA Y, OTSUKA T, HOTOKEBUCHI T, et al.: Effect of IL-10 on collagen-induced arthritis. Inflamm. Res. (1996) 45:283–288.
   PubMed Web of Science ®Google Scholar
• SEKUT L, YARNALL D, STIMPSON SA, et al.: Anti-inflammatory activity of phosphodiesterase (PDE) IV inhibitors in acute and chronic models of inflammation. Clin. Exp. ImmunoL (1995) 100:126–132.
   PubMed Web of Science ®Google Scholar
• CHIKANZA IC, JAWED SJ, BLAKE DR, et al.: Treatment of patients with rheumatoid arthritis with RP 73401 phosphodiesterase Type IV inhibitor. ACR 60th National Scientific Meeting. Orlando, Florida (1996).
   Google Scholar
• HANIFIN JM: Atopic dermatitis: new therapeutic considerations. I Am. Acad. DermatoL (1991) 24:1097–1101.
   PubMed Web of Science ®Google Scholar
• TEIXEIRA MM, ROSSI AG, WILLIAMS TJ, HELLEWELL PG: Effects of phosphodiesterase isoenzyme inhibitors on cutaneous inflammation in the guinea-pig. Br. I Pharmacol. (1994) 112:332–340.
   PubMed Web of Science ®Google Scholar
• HANIFIN JM, CHAN SC, CHENGJB et al.: Type 4 phosphodiesterase inhibitors have clinical and in vitro anti-inflammatory effects in atopic dermatitis. I Invest. Dermatol. (1996) 107:51–56.
   Google Scholar
• SAWISKI MA, RUSIN LJ, BURNS TL, WEINSTEIN GD, VOORHEES JJ: Ro 20-1724: an agent that significantly improves psoriatic lesions in double-blind clinical trials. I Invest. DermatoL (1979) 73:261–263.
   PubMed Web of Science ®Google Scholar
• BLOXHAM DP: Therapeutic applications of anti-TNF monoclonal antibodies. Exp. Opin. Invest. Drugs (1994) 3:907–912.
   Google Scholar
• KUHN R, LOHLER J, RENNICK D, RAJEWSKY K, MULLER W: Interleukin-10-deficient mice develop chronic enterocolitis. Cell (1993) 75:263–274.
   PubMed Web of Science ®Google Scholar
• GENAIN CP, ROBERTS T, DAVIS RL, et al.: Prevention of autoimmune demyelination in non-human primates by a cAlVIP-specific phosphodiesterase inhibitor. Proc. Natl. Acad. Sci. USA (1995) 92:3601–3605.
   PubMed Web of Science ®Google Scholar
• STURGESS I, SEARLE GF: The acute toxic effect of the phosphodiesterase inhibitor rolipram on plasma osmolality. Br. I Clin. PharmacoL (1990) 29:369–371.
   PubMed Web of Science ®Google Scholar
• CHIU N, PARK I, REID IA: Stimulation of renin secretion by the phosphodiesterase IV inhibitor rolipram.I PharmacoL Exp. Ther. (1996) 276:1073–1077.
   PubMed Web of Science ®Google Scholar
• HADLEY AJ, KUMARI M, COVER PO, et al.: Stimulation of the hypothalamic-pituitary-adrenal axis in the rat by the type 4 phosphodiesterase (PDE-4) inhibitor, denbufylline. Br. I PharmacoL (1996) 119:463–470.
   PubMed Web of Science ®Google Scholar
• CHENG JB, WATSON JW, SHOWELL HJ, et al.: CP-80,633 elevates plasma cAlVIP levels and decreases TNF production in mice: effect of adrenalectomy. I Allergy Clin. Immunol. (1995) 95: 351.
   Google Scholar
• SCHUDT C, TENOR H, LOOS U, et al.: Effects of selective PDE inhibitors on activation of human macrophages and lymphocytes. Eur. Resp. 1 (1993) 6\(Suppl. 17):3675.
   Google Scholar
• R &D Focus Database. IMS World Publications Ltd.
   Google Scholar
• Highlights of SmithKline Beecham's R&D Portfolio. Marketletter (2 January, 1995):22–23.
   Google Scholar
• WATSON JVV, BECK R, COHAN VI, et al: Anti-anaphylactic and side-effect activity of the PDEIV inhibitor CP-80,633. J. Allergy Clin. ImmunoL (1995) 95\(Part 2):353, Abstract 850.
   Google Scholar
• COHAN VL, SHOWELL HJ, FISHER DA, et al.: In vitro pharmacology of the novel phosphodi-esterase Type 4 inhibitor, CP-80633.i PharmacoL Exp. Ther. (1996) 278:1356–1361.
   PubMed Web of Science ®Google Scholar
• TURNER CR, COHAN VL, CHENG JB, et al.: The in vivo pharmacology of CP-80,633, a selective inhibitor of phosphodiesterase 4.1 PharmacoL Exp. Ther. (1996) 278:1349–1355.
   Google Scholar
• IVVASAKI T, KONDO K, KURODA T, et al.: Novel selective PDEIV inhibitors as antiasthmatic agents. Synthesis and biological activities of a series of 1-aryl-2,3-bis(hydroxymethyl)naphthalene lignans. J. Med. Chem. (1996) 39:2696–2704.
   PubMed Web of Science ®Google Scholar
• KANIINUMA O, MORI A, SUKO M, et al.: A novel phosphodiesterase inhibitor, T-440: possible management of eosinophilic inflammation by down-regulation of Interleukin-5 production. Int. Arch. Allergy ImmunoL (1996) 111\(Suppl. 1):16–18.
   PubMed Web of Science ®Google Scholar
• SOUNESS JE, RAO S: A proposal for pharmacologically distinct conformers of PDE4. Cell. Signalling (1997) 9. In press.
   PubMedGoogle Scholar
• SCHNEIDER HH, SCHMIECHEN R, BREZINSKI M, SEIDLER J: Stereospecific binding of the antidepressant rolipram to brain protein structures. Eur. I PharmacoL (1986) 127:105–115.
   PubMed Web of Science ®Google Scholar
• WARD A, CLISSOLD SP: Pentoxifylline: a review of its pharmacokinetic properties, and its therapeutic efficacy. Drugs (1987) 34:50–97.
   PubMed Web of Science ®Google Scholar
• JONES TR, MCAULIFFE M, MCFARLANE C, et al.: Effects of a selective PDE IV inhibitor (CDP 840) in a leukotriene-dependent non-human primate model of allergic asthma. Am. J. Respir. Crit. Care Med. (1996) 153:A346.
   Google Scholar